FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of Pemgarda™ (Pemivibart) to Include Treatment of Mild-to-Moderate Covid-19 for Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing Pemgarda Eua for Pre-Exposure Prophylaxis of Covid-19 in Certain Immunocompromised Patients